Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.18
ARRY's Cash to Debt is ranked higher than
57% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ARRY: 1.18 )
ARRY' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 1.18

Equity to Asset -0.04
ARRY's Equity to Asset is ranked lower than
51% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARRY: -0.04 )
ARRY' s 10-Year Equity to Asset Range
Min: -1.55   Max: 0.93
Current: -0.04

-1.55
0.93
F-Score: 3
Z-Score: -5.13
M-Score: -1.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -56.83
ARRY's Operating margin (%) is ranked higher than
72% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ARRY: -56.83 )
ARRY' s 10-Year Operating margin (%) Range
Min: -410.11   Max: -12.98
Current: -56.83

-410.11
-12.98
Net-margin (%) -89.02
ARRY's Net-margin (%) is ranked higher than
68% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ARRY: -89.02 )
ARRY' s 10-Year Net-margin (%) Range
Min: -511.63   Max: -12.77
Current: -89.02

-511.63
-12.77
ROA (%) -45.55
ARRY's ROA (%) is ranked higher than
61% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ARRY: -45.55 )
ARRY' s 10-Year ROA (%) Range
Min: -134.46   Max: -4.15
Current: -45.55

-134.46
-4.15
ROC (Joel Greenblatt) (%) -393.49
ARRY's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. ARRY: -393.49 )
ARRY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -393.49   Max: -16.66
Current: -393.49

-393.49
-16.66
Revenue Growth (%) -15.30
ARRY's Revenue Growth (%) is ranked higher than
66% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. ARRY: -15.30 )
ARRY' s 10-Year Revenue Growth (%) Range
Min: -23.5   Max: 39.4
Current: -15.3

-23.5
39.4
EBITDA Growth (%) -27.10
ARRY's EBITDA Growth (%) is ranked higher than
60% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. ARRY: -27.10 )
ARRY' s 10-Year EBITDA Growth (%) Range
Min: -65.7   Max: 101.4
Current: -27.1

-65.7
101.4
EPS Growth (%) -28.40
ARRY's EPS Growth (%) is ranked higher than
62% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. ARRY: -28.40 )
ARRY' s 10-Year EPS Growth (%) Range
Min: -50.5   Max: 55.7
Current: -28.4

-50.5
55.7
» ARRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ARRY Guru Trades in Q1 2013

Steven Cohen 34,291 sh (New)
Paul Tudor Jones Sold Out
Jim Simons 73,700 sh (-86.39%)
» More
Q2 2013

ARRY Guru Trades in Q2 2013

Steven Cohen Sold Out
Jim Simons Sold Out
» More
Q3 2013

ARRY Guru Trades in Q3 2013

Jim Simons 586,752 sh (New)
» More
Q4 2013

ARRY Guru Trades in Q4 2013

Jim Simons 363,852 sh (-37.99%)
» More
» Details

Insider Trades

Latest Guru Trades with ARRY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2011-12-31 Sold Out 0.0024%$1.77 - $2.83 $ 3.7966%0
George Soros 2011-12-31 Sold Out 0.0008%$1.77 - $2.83 $ 3.7966%0
George Soros 2011-09-30 New Buy$1.99 - $2.62 $ 3.7969%22400
George Soros 2011-06-30 Sold Out $2.06 - $3.21 $ 3.7940%0
Jean-Marie Eveillard 2011-06-30 Add 150%$2.06 - $3.21 $ 3.7940%250000
Jean-Marie Eveillard 2011-03-31 New Buy$2.7 - $3.29 $ 3.7926%100000
George Soros 2011-03-31 New Buy$2.7 - $3.29 $ 3.7926%14400
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 7.06
ARRY's P/S is ranked higher than
62% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. ARRY: 7.06 )
ARRY' s 10-Year P/S Range
Min: 1.43   Max: 16.57
Current: 7.06

1.43
16.57
EV-to-EBIT 55.60
ARRY's EV-to-EBIT is ranked lower than
74% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ARRY: 55.60 )
ARRY' s 10-Year EV-to-EBIT Range
Min: 6082.4   Max: 8002.5
Current: 55.6

6082.4
8002.5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.20
ARRY's Price/Median PS Value is ranked higher than
58% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ARRY: 1.20 )
ARRY' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 2.59
Current: 1.2

0.25
2.59
Forward Rate of Return (Yacktman) -58.90
ARRY's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ARRY: -58.90 )
ARRY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -77.3   Max: -61
Current: -58.9

-77.3
-61

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AR2.Germany
Array BioPharma, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across various therapeutic areas. The Company is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib partnered with AstraZeneca, MEK162 partnered with Novartis, and danoprevir, an NS3 protease inhibitor, partnered with InterMune / Roche, having the potential to begin pivotal trials by the end of calendar year 2013. The Company's proprietary clinical programs include ARRY-520, ARRY-614, ARRY-797, and ARRY-502. The Company's internal drug discovery programs include inhibitors that target Trk receptors for the treatment of pain and G-protein-coupled receptor 119 for the treatment of diabetes. The Company competes with companies worldwide that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations. The Company is subject to substantial regulation by governmental agencies in the U.S. and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide